BioCentury
ARTICLE | Translation in Brief

Systems biology orders strategy to avoid cross-drug resistance in cancer

A Harvard and Mitra Biotech team use systems biology modeling to uncover a three-drug regimen that bypasses breast cancer resistance

August 22, 2019 6:22 PM UTC

A Harvard and Mitra Biotech team used systems biology to identify a temporal treatment regimen that uses a glucose metabolism inhibitor to overcome cross-drug resistance in breast cancer.

Chemotherapies are often administered in combination regimens to make it harder for tumors to resist treatment. But aggressive cancers including including triple-negative breast cancer (TNBC) often develop resistance or tolerance to combination regimens, said Aaron Goldman, who-co led the team...